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tb and hiv
the failure to act
 “I get frustrated and sad when people die, whilst 
there is treatment available for them that could have 
made them better and allow them to live on for many 
good years and enjoy their lives.” 
— MSF medical staff member in Nchelenge district, 
Zambia.
tb and hiv
the failure to act 
eXecutive SuMMarY
Tuberculosis (TB) and HIV/AIDS are intricately linked. There are currently 
 million people ‘co-infected’ with both diseases and half of all deaths of 
HIV- positive people are due to TB.
Although there is growing international recognition of the nature of 
the relationship between the two diseases, there is a massive failure 
to respond to the dual epidemic in an integrated way. Despite clear 
statements from the World Health Organisation and others on the 
importance of implementing a joined-up approach, TB and HIV 
programmes continue to work in isolation from each other. 
This must change. For people infected with both HIV and TB, to treat one 
disease is not enough. Patients receiving HIV treatment can still die of TB, 
and patients being treated for TB often still die from AIDS.
Médecins Sans Frontières (MSF) currently runs TB projects in 44 countries 
and HIV/AIDS projects in  countries around the world. Based on our 
experience on the ground, MSF believes that the global response to these 
diseases remains shockingly inadequate. Urgent action is needed to 
combat TB and HIV and stop the rising tide of needless deaths. 
The most important steps to be taken are: 
•  Routine HIV testing and care must be made available for all TB patients;
•  All HIV/AIDS patients must have access to early diagnosis and 
treatment of TB;
•  Six month TB treatment regimens must be used and the ‘DOTS’ 
approach must be adapted on the ground to cope with the effects of the 
HIV epidemic;
•  Support for research and development is desperately needed to ensure 
that better tools for diagnosing and treating TB are found, and in the 
longer term that effective TB and HIV vaccines will be developed.4 
introduction
This report describes MSF’s experience of treating people who are infected 
with both HIV and tuberculosis (TB). Through programmes in Africa and 
Asia, MSF is struggling to ensure that people with these diseases receive 
proper treatment and no longer die unnecessarily. 
Effective TB treatment became available in developed countries 40 
years ago and it is more than 0 years since effective AIDS treatment 
was introduced in the West. Yet the vast majority of those infected with 
these two diseases today live in the world’s poorest countries and still die 
needlessly due to a failure of disease diagnosis and lack of access to the 
treatment.
Governments and institutions across the globe have committed 
to making dramatic reductions in the rates of both diseases and to 
ensuring that everyone receives the treatment they need. However, 
MSF’s experience in trying to provide care is that there is little evidence 
of progress in the poorest countries and communities where these 
epidemics have a fatal grip. In Africa, of all the people infected with both 
diseases, fewer than % are getting the drugs that they desperately need . 
MSF has shown that it is possible to treat people with these infections in 
the most difficult settings, through using innovative ways of finding, 
diagnosing, and treating patients. But we are hampered by the outdated 
and ineffective tools available for diagnosis and treatment and a lack of 
research.
The aim of this report is to highlight the effects of these two diseases 
on people’s lives and to share MSF’s field experience: what works in 
attempting to provide treatment and combat these dual epidemics, what 
is failing, and what urgently needs to be addressed to prevent many more 
people dying.
Note: names of some patients have been changed to protect their anonymity.
zaMbia
An estimated 1 million people in Zambia are 
living with HIV/AIDS. In rural areas health 
services are limited. In one of these areas, 
Nchelenge district in the northeast, MSF is 
providing antiretroviral treatment to over 
1,000 people living with HIV/AIDS. Each month, 
there are 45 new patients. MSF screens these 
patients for TB and works with Zambian health 
authorities to initiate further treatment in case 
of co-infection.

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tb and hiv: 
a deadlY coMbination
Tuberculosis kills around two million people every year. TB is the major killer of people living with 
HIV: up to half of all deaths of HIV patients are due to TB. A patient with both diseases can be four 
times more likely to die during TB treatment than someone being treated for TB alone.

The spread of HIV is fuelling the rise of TB in many 
regions of the world. In parts of Africa, more than half 
of those infected with TB also have HIV. MSF doctors in 
countries with the highest HIV prevalence rates, such 
as Lesotho and Zimbabwe, find that over % of TB 
patients are HIV-positive. 
“The situation is very urgent. TB is the biggest silent killer 
of HIV patients in Africa.” 
	 —		Dr	Charles	Ssonko,	Medical	Team	Leader	for	
MSF,	Zambia.
While HIV rates are not as high in most of Asia, TB and 
HIV remain major problems among ‘high risk’ groups 
such as intravenous drug users and sex workers. Rising 
HIV rates, along with increasing resistance to TB drugs, 
mean that poorer countries in Asia struggle to control 
these diseases. 
For people infected with both HIV and TB, to treat one 
disease is not enough. Patients receiving HIV treatment 
can still die of TB, and patients treated for TB often still 
die from AIDS.
“It was only after the TB that they discovered that I was 
HIV positive. The TB exposed my HIV.” 
	 —	Mary,	53	years	old,	Nigeria.	Co-infected	patient.	
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tb and hiv 
By the end of 2006 there were an estimated 39.5 million people living with HIV 
worldwide. In that year 2.9 million of them died. Currently, 9 million people 
develop TB each year and 2 million die of the disease. 11 million people are 
infected with both diseases.   
The HIV virus itself doesn’t kill. It weakens the immune system by destroying 
CD4 cells, which usually defend against infection. Most people will remain 
healthy for many years after contracting HIV . Only after around five to ten 
years, when the virus has severely damaged the immune system, do people 
progress to the next stage – AIDS. 
AIDS is diagnosed when a defined set of clinical conditions are found in a 
person infected with HIV . These conditions are mostly infections that occur 
once the immune system is unable to fight them – so called ‘opportunistic 
infections’. TB is one of the most common ‘opportunistic infections’ in people 
with HIV .
TB is caused by a bacterium called Mycobacterium tuberculosis. Infection usually 
happens by inhalation of bacteria released when an infected person coughs or 
sneezes. Globally about one in three people are infected with TB, but most will 
not become sick since the immune system in healthy people is usually able to 
prevent the infection from progressing to the active disease.
When someone is co-infected with TB and HIV , the damage to the immune 
system caused by HIV means that they are less able to fight TB infection. 
As HIV progresses, the immune system becomes weaker and the risk of 
developing active TB disease increases. 
As a result, people with HIV infection are up to 20 times more likely to develop 
TB disease than people who are not infected with HIV. For AIDS patients 
who take antiretroviral treatment the risk of developing TB is much lower, but 
remains 4-8 times higher than people who do not have HIV4. 
In addition, due to their weakened immune system, TB more often infects areas 
of the body outside the lung in someone with HIV , leading to ‘extra-pulmonary 
TB’. For example, it can infect the spine (which can cause paralysis), the 
kidneys, the lymph nodes, or the lining of the brain (TB meningitis). Many of 
these forms of the disease are difficult to diagnose and are much more common 
in people with HIV .
TB causes death in a number of ways. It can spread through the infected organ 
(lung, kidney, bone, brain, etc) and stop it from working. In TB of the lung, 
much of the lung tissue can be destroyed. TB not only weakens the immune 
system further, it also causes loss of appetite so that patients stop eating and 
become emaciated. This further reduces their ability to fight infection.
2
tb and hiv 
can be treated 
Once someone with HIV is infected with TB, effective treatment is still possible. The sooner people 
with HIV start TB treatment, the greater chance they have of surviving. Cotrimoxazole, an 
antibiotic, must be added to the treatment of all TB patients known to have HIV; this simple addition 
can reduce the death rate during TB treatment by 40% .
Similarly, the sooner co-infected patients start to take 
antiretroviral (ARV) drugs to treat HIV, the better 
the chances of survival and cure. Without ARVs, co-
infected patients are likely to die from TB or other 
infections during or soon after TB treatment. A study 
in Thailand found that % of co-infected patients 
who received ARVs were alive after  years of treatment 
– compared with just % of patients who, before ARVs 
were available, received only TB treatment.
It is therefore vital that TB patients are tested for HIV 
and that they are put on effective treatment if found to 
be HIV-positive. Yet, shockingly, only % of co-infected 
patients in Africa are tested and found to be positive 
– and only 0.0% receive anti-retroviral treatment .
When patients receive treatment for their illnesses, 
their lives can be transformed, and they start to hope 
and plan for their and their family’s futures. 
“Just after I was tested for TB and HIV and when I was 
so very ill, I felt so depressed about being sick and not 
being able to provide for my family that I thought about 
suicide a couple of times. When I heard about ARVs and 
that treatment for HIV patients is possible, I started to 
get hope. I started the ARV treatment in November 2005 
and started feeling better quickly. Now, I feel much better. 
I still have HIV of course, but with the ARVs I am able to 
work and provide for my family. For the near future I hope 
to earn some money to buy fertilizer for my land, in order 
to be a better farmer. One day I hope to get back to work as 
a salesperson – that is what I did before I got sick. I have a 
family of seven children.” 
	 —		Peter,	40	years	old,	married,	seven	children,	
Zambia.	He	had	been	co-infected	with	TB	and	
HIV.
2.1 MSf’S eXperience of treating 
patientS with tb and hiv
MSF has been providing care for people with TB since 
the early 0s. The focus has largely been on treating 
people in areas with no government TB programme 
and targeting groups neglected by their governments. 
These groups have included nomadic populations in 
Sudan, war-affected people in Afghanistan, Somalia, 
and Chechnya, and prisoners in Russia with multi-drug 
resistant TB. In 00, over ,000 people were treated 
for TB by MSF teams in 4 projects in 44 countries. 
Many more patients were referred  by MSF for treatment 
within national TB programmes. 
MSF began caring for HIV patients in the early 0s 
and started providing ARV drugs in 000. Since then, 
MSF has successfully provided treatment in many 
countries around the world, even in remote and 
conflict affected areas. Thanks to a major campaign 
for access to medicines, huge reductions in the prices 
of HIV drugs have allowed many more people to start 
treatment. Today there are over 0,000 people on HIV 4 
living with tb and hiv
Through our programmes, we witness the effect that living with HIV and TB has on individuals and 
communities. As well as the physical effects of their illness, people have to deal with stigma from 
friends, family, the community, and, all too often, the health-care workers who should be supporting 
them. People living with HIV/AIDS and TB are often very poor and their situation is worsened if 
they are too sick to work or are refused work because of the stigma attached to their illness. Often 
they live far from health centres and can ill-afford the costs of transport and the time away from 
work to get care. If they do access care it can often be financially crippling for them and their 
families if they have to pay for drugs or treatment. 
On top of social stigma and the costs of health care, it is also difficult for people to get a timely, 
accurate diagnosis and to access treatment. This effectively means that HIV patients are denied 
care for TB in many settings.
“I felt really down and was dating a guy and we decided to go to the clinic together. We both tested positive 
[for HIV] in July 2001. For a whole month I couldn’t move out of bed. My mother had to look after me, clean 
my body, mop me and feed me. I was coughing a lot and couldn’t do anything for myself. But somehow I 
picked up again and I went to Lagos General University Hospital. All they could do was to give me multi-
vitamins and supplements. I wasn’t tested for TB. I think they just saw I had HIV and they didn’t bother.” 
— Diane, 26 years old, Nigeria. She is co-infected with TB and HIV .
“I had diarrhoea, fever, and my lymph nodes were swollen. I thought it would pass. So I did nothing but I 
became weaker and weaker. I suspected it was TB but I could not afford a treatment. I heard about the MSF 
clinic where you get treatment for free. Elsewhere the treatment costs a lot of money. 
The diagnosis was TB and I started treatment. In the beginning I felt a bit giddy and my fingers tingled. But it 
didn’t last long. The treatment was not so difficult. When I came here I did a test for HIV. When they told me I 
was HIV+, I was in pieces. 
Every month I come to the clinic for my pills. If I take my pills it will go fine. I don’t want to think about death. 
When my husband was sick his family didn’t tell me that he had TB and that he was HIV+. They said he had a 
liver disease. He had a TB treatment but he didn’t take his pills regularly. Then he stopped the treatment. He 
passed away at home.
If I take my pills carefully I can do things and care for my children. Now I’m already much better. Before I felt 
inferior because I have the disease I’ve felt not a complete human being. In the house of my sister, I eat alone. 
They didn’t ask it directly but I knew they preferred it. First it made me sad but now I think they don’t know 
much about HIV/AIDS. I hope one day they will understand more. These days they ask me at their table and 
sometimes I join them.
My husband should have told me openly what his status was. In that case he would be alive today. I wouldn’t 
have the disease. I could have helped him.”
—   Lucy, 32 years old, Myanmar. She is taking ARVs for her HIV infection and finished her TB treatment 
a month prior to being interviewed. Her husband died a year ago and now she and her 5-year-old 
daughter live with her sister. Her sons, aged 7 and 12 years, live with her husband’s family. 
treatment in MSF programmes in  countries, over 
,000 of them children under 4 years. 
“I trained here 12 years ago in 1994/95. When a patient 
came in with HIV he was always put in the last bed by the 
toilet. Most times nothing was done for them because the 
belief was that there was no hope for these ones. So I think 
when MSF came to treat opportunistic infections, and 
they could actually see these people walk home, it makes a 
difference.” 
	 —		Agnes	Akporotu,	MSF	nurse,	Lagos	General	
Hospital,	Nigeria.
nigeria
In the capital Lagos, MSF is providing over 1,300 
patients with antiretroviral treatment. Patients 
co-infected with TB are treated in partnership 
with the TB clinic in the Lagos General Hospital.

Photos: Ton Koene Diagnosing TB is already difficult in resource-poor 
settings, but is especially challenging amongst people 
who are infected with HIV. Treating both diseases 
together can be complex and costly and is made 
more difficult because the established public health 
approach to treating TB does not serve people with HIV 
well.
3.1 difficult diagnoSiS
Tuberculosis
The tools available to diagnose tuberculosis have 
changed little in the last 00 years, due to an abysmal 
lack of research and development in this area. This 
means that, with the exception of those patients 
who are producing large quantities of bacteria in 
their sputum, most cases of TB remain very difficult 
to diagnose. The result is that many TB cases go 
undiagnosed or are diagnosed very late – often too late. 
Because people living with HIV/AIDS develop patterns 
of TB disease that are especially difficult to diagnose it 
is even harder for them to get treatment. 
The standard test for TB, known as sputum microscopy, 
was developed in . A sputum sample is collected 
and stained to show up TB bacteria and then examined 
under a microscope. While this technique is the 
simplest way of diagnosing TB, it requires well trained 
staff and well collected and handled specimens. It will 
give a positive result only if there is TB in the patient’s 
lungs and they can cough up enough sputum for it to 
be detected. Fewer than 0% of actual TB cases can be 
diagnosed using this test .  
Some patients with TB of the lung do not cough up 
enough bacteria to be detected by sputum microscopy. 
This is especially common in people with HIV. A 
technique called sputum culture is better at detecting 
low numbers of bacteria but won’t find all cases. It 
is also a slow test, taking anything between one and 
six weeks to provide a result. Furthermore, because it 
requires a sophisticated laboratory, it is rarely available 
in resource-limited settings. 
“I remember one young man who was very sick. He had 
HIV and I couldn’t diagnose for TB. He was not coughing, 
but he was losing weight fast. We did the TB tests: sputum 
test and X-ray were negative. The only thing that made 

A study carried out at the MSF project in 
Khayelitsha, South Africa, found that only 
16.5% of TB patients, most of whom also had 
HIV , gave a positive result when tested by 
sputum microscopy. However, 49% of those 
patients with negative results had positive 
results when tested with the more sensitive 
culture method. 
0
3
whY iS tacKling tb and hiv 
difficult?
Responding to these dual epidemics is a huge challenge, particularly in resource-poor settings where 
health systems are already struggling to cope. Because many people develop active TB disease in 
areas where HIV is common, an extra strain is put on weak health services.   
me suspect he had TB was his swollen and fluid-filled 
abdomen. I wanted to start TB treatment but the Ministry 
of Health protocol wouldn’t allow it. 
Eventually, we transferred him to Lusaka, the capital city 
of Zambia. Here he could start the treatment because the 
Ministry of Health representatives in the capital accepted 
the local doctor’s diagnosis of TB on a clinical basis. The 
lack of the right diagnostic tools caused a treatment delay 
of two months. 
This man was lucky because he could go to Lusaka. Many 
other patients cannot move, and die in this process of 
delay.” 
	 —	Dr	Charles	Ssonko,	Medical	Team	Leader	for	
MSF,	Zambia.
A chest X-ray will often show signs of TB in the lungs, 
and can be useful to support a pulmonary TB diagnosis 
when the sputum test is negative. However, it is still 
easy to miss TB or to mistake X-ray signs of another 
disease for TB. This is especially true for patients co-
infected with TB and HIV in whom the X-ray signs are 
rarely typical.
In most remote clinics, the only way that TB can be 
diagnosed is the microscopic examination of sputum, 
the clinical skills of the health worker, and occasionally 
a chest X-ray. Since many people infected with TB do 
not present with typical symptoms, or with a cough, 
they are often missed. 
“The symptoms of TB are a cough, sometimes with blood; 
fever; night sweats; and – especially with HIV infection 
– weight loss. In co-infected patients, weight loss can be 
the only feature. However, it can be confusing because 
other conditions associated with HIV can also present 
with weight loss as the only feature. Hence the difficulty in 
making an accurate diagnosis.” 
	 —		Dr	Kalpana	Sabapathy,	HIV	Coordinator,	
Yangon,	Myanmar.
children are particularlY 
neglected
The most neglected of all those suffering from TB and/or HIV are children. 
HIV cannot be diagnosed in infants without expensive, complex medical equipment. 
Even when they do not have HIV , the problems of diagnosing TB are greater in 
children than in adults. It is rare to achieve a definitive diagnosis of TB in co-infected 
children without equipment that, for most, is out of reach.
“In 1994 we started TB treatment for undernourished children. Young children do not produce 
sputum and the diagnosis had to be entirely based on clinical judgement.” 
—   Dr Frank Smithuis, MSF Head of Mission and Medical Coordinator, Myanmar.
Children with TB and HIV develop disease more quickly and die more quickly. The 
drugs needed to treat both TB and HIV are not available in child-friendly palatable 
liquid forms, nor are tablets small enough for young children to swallow. When drugs 
are available they are often very expensive. 
MSF is increasingly focused on getting children with HIV and TB onto treatment but 
globally far too little is being done. National programmes neglect children, or leave 
them until adults are treated. Drug companies see no profit in researching better 
diagnostic tools or drugs for children in poor countries. 
hiv
The challenges associated with diagnosing HIV are 
quite different in nature to those of diagnosing TB. 
Compared with the technical difficulties of diagnosing 
TB, HIV infection is much easier to identify. The HIV 
test can be carried out in less than 0 minutes and is 
very accurate. 
However, making sure that people actually get tested 
for HIV is a major stumbling block. This is partly 
due to the significant social stigma often attached 
to being HIV positive. In some cases HIV testing is 
offered but refused, in others it is simply not available. 
Unacceptably, in many areas where HIV testing is 
available, it is not routinely offered to TB patients. 
Today, many TB patients remain untested for HIV – it is 
estimated that in Africa only % of those who are 
co-infected actually know that they have HIV.
“Especially TB patients refuse to get tested for HIV. I 
estimate that only 5 to 10% of TB patients get tested for 
HIV. When they test positive for TB, patients are relieved 
that they can tell themselves and their family it was just 
TB and not HIV.” 
	 —		MSF	clinical	officer,	Nchelenge	district,	
Zambia.
3.2 tb treatMent iS outdated
Lack of interest in developing better drugs has meant 
that there has been no improvement in the treatment 
used for TB since the 0s. The treatment is lengthy 
and can be problematic in patients who also have HIV. 
There is a desperate need for shorter more effective 
treatments. While research has increased in the last 
few years, there has been no new drug entering wide 
use in over 0 years, and affordable, effective new drugs 
remain a distant hope.
There are simply not enough promising drugs in 
the pipeline and serious funding gaps prevent the 
development of candidate drug compounds through to 
clinical trials. Worldwide, only US$0 million per year 
is currently spent on clinical trials for TB drugs.
tb and hiv 
treatMent
The drugs used in TB treatment are rifampicin, 
isoniazid, ethambutol, and pyrazinamide. All four are 
given daily in combination for the first two months of 
treatment – the intensive phase. 
During the second part of the treatment – the 
maintenance phase – many countries use a further six 
months of ethambutol and isoniazid. However, four 
months of daily rifampicin and isoniazid is far more 
effective in patients co-infected with TB and HIV. 
Regrettably, slightly greater expense and concerns 
that resistance to rifampicin could develop in poorly 
managed programmes have stopped this protocol 
from being widely used. This is despite World Health 
Organisation recommendations. In any case, both 
treatments are so lengthy that many do not complete 
their courses. 
A further complication is that some of the commonly 
used ARVs, such as nevirapine, cannot be taken 
together with rifampicin, a vital part of TB treatment. 
In poor countries the alternatives to rifampicin are 
too expensive, and efavirenz (an alternative ARV to 
nevirapine) is more expensive and cannot be taken in 
early pregnancy. 
In addition, the number of tablets a co-infected patient 
needs to take each day is high, making it harder for 
them to stick to their treatment properly. They also 
tend to suffer from more side-effects from the drugs, 
which again makes it especially tough for co-infected 
patients to adhere to the treatment regimen. 
“It’s not easy taking all the drugs. I take two tablets for my 
TB every morning at 6 am and then for my HIV I take one in 
the morning and three at night. I get pains in my legs and 
headaches and sometimes I don’t want to take the drugs, 
but I do my best.”
—   Margaret, 40 years old, Nigeria. She is co-infected 
with TB and HIV .4 
3.3 lacK of huMan reSourceS 
There are tens of thousands of co-infected people in 
desperate need of diagnosis and treatment, but very 
few health-care workers available to provide it. Simply 
piling more work onto the few existing staff will not 
work. If TB and HIV patients are to receive effective care 
there must be sufficient trained and motivated staff 
available to look after them.
3.4 StigMa
Stigma can be a major difficulty in responding 
effectively to these diseases. People are often reluctant 
to test for HIV out of fear of the disease itself, and fear 
of the stigma that is attached to HIV. 
“Patients tell me, I can not handle it to have two major 
diseases. I have TB now, please stop asking me to get tested 
for HIV as well. It is too much for me.” 
	 —		MSF	Clinical	Officer	in	Nchelenge	district,	
Zambia.
Stigma can be deadly. It can lead to people refusing to 
get tested until it is too late, by which time they are too 
sick for the treatment to work.
“After being diagnosed as having both diseases, Alison died 
within 6 months. She was already too sick for the medicine 
to help her. At the end of her life, she had pus in her lungs. 
They took five litres of liquid out of her chest. It was a 
terrible way to die. 
I think if Alison had gone to the clinic earlier to get 
treatment for her illnesses, she would have been alive 
today. Alison was a good person, I miss her very much. She 
left behind four children.”
	 —	Sarah	talks	about	her	sister	Alison	(29	years	
old)	who	died	of	HIV	and	TB	co-infection	in	
Zambia.
As more people are tested and benefit from treatment, 
stigma is slowly decreasing in some places. However, it 
remains the responsibility of all involved with care and 
testing for HIV to ensure that they help address stigma, 
and help people living with HIV/AIDS to overcome it.
“All my family and friends now know I am HIV positive. 
Many more people are talking about this disease now. 
The stigma is not so big anymore. In the past that was 
different, a lot of people died because they didn’t want 
to know they were sick and refused to get tested. For me 
there is no stigma now anymore: HIV for me is the same 
as having malaria. It is treatable. I am glad I speak about 
this disease with friends and family. When I meet other 
patients who don’t, I tell them that when you keep it for 
yourself, the burden can be very heavy. If you share it, 
maybe it is easier to handle this disease.” 
	 —		Masautso,	37	years	old,	a	Voluntary	
Community	Worker,	Zambia,	who	is	co-
infected	with	TB	and	HIV.	He	helps	to	detect	
and	take	care	of	TB	and	HIV	patients.	
3.5 econoMic conSequenceS
TB and HIV disproportionately affect poor people who 
were often already struggling to support themselves 
before they were infected. Getting sick can be a 
catastrophe for people who do not have anyone to 
support them. Whole families are devastated when an 
income is lost because someone becomes ill and is too 
sick to work.
 
“Physically, I am not feeling well at all. I feel sick all the 
time and I cannot work. I am a farmer, I have a cassava and 
vegetable field. Currently nobody is working the field so we 
have no income.” 
	 —		Simon,	36	years	old,	Zambia.	He	was	first	
diagnosed	with	TB	and	later	with	HIV.
If treatment is not free, only the wealthiest patients will 
be able to afford it. The cost of ARVs and hospital care 
is such that even the most well-off often impoverish 
themselves trying to pay medical bills. They can end 
up being forced to sell land and livestock, to take 
their children out of school, and eventually to stop 
treatment. 
“The TB medication seems to be working because I feel a 
bit better now than when I first got sick and I have gained 
weight a bit. I have only been taking the ARVs for three 
weeks, I don’t feel any different yet. I am very happy that 
I get the medicines for free. If I would have to pay for it, I 
would be lost. I don’t have any money, so I would just die.” 
	 —		Andrew,	36	years	old,	Zambia.	He	was	first	
diagnosed	with	TB	and	later	with	HIV.
On top of the expense of treatment, the cost of 
transport can be prohibitive. In poor, rural areas, 
patients may live very far from treatment centres and as 
a result are often unable to afford the cost of fares and 
the time lost working to go and receive treatment. 
“The treatment is not difficult itself, but financially it is 
hard. My husband repairs bicycles and is not earning a lot. 
The transport is very expensive. A big part of his income is 
used to pay for my bus ticket to the clinic.” 
	 —		Sonya,	Myanmar.	She	is	co-infected	with	TB	
and	HIV.
3.6 nutritional Support iS aS 
iMportant aS drugS
Without adequate food and nutrition, drugs cannot 
cure TB. People with TB and HIV are often 
malnourished and find it particularly hard to get 
proper nutrition. It is essential that they are given free 
nutritional support. This has long been part of the 
accepted standard for treatment of TB, but is all too 
often lacking in the response to HIV. 
“Nutrition is a problem. Even if you get the treatment it 
doesn’t mean you can afford food.” 
	 —		Simon,	community	worker	in	a	project	for	
people	living	with	HIV/AIDS,	Myanmar.	He	is	
co-infected	with	TB	and	HIV.
3.7 drug reSiStant tb
TB will become resistant if it is not exposed to several 
drugs at the same time. To further reduce the risk of 
resistance developing, the drugs used in TB treatment 
must not be available outside TB programmes. In parts 
of the world where TB drugs have been made available 
without ensuring they were only used in combination 
and for TB treatment, resistance to the drugs is 
common. This means that it can be very difficult in 
poor countries to test for which drugs will be effective.
“In the West, testing for drug sensitivity is more easy. 
They can take the bug, culture it and test it for which drug 
it is sensitive to and for which it is not. This option is not 
available in Myanmar at the moment. In the case of drug 
resistance you are shooting in the dark because you don’t 
know which drugs will work.”
	 —		Dr	Frank	Smithuis,	Head	of	Mission	and	
Medical	Coordinator,	Myanmar.
Where the TB is resistant to most of the routine TB 
drugs, second-line drugs are needed. These are very 
expensive, have many side-effects, require a long 
course of treatment and often have poor outcomes. 
Most patients in developing countries do not have 
access to these drugs.
In some countries, multi-drug resistance has become a 
major problem. Where patients have both resistant TB 
and HIV the outlook is very poor. Multi-drug resistant 
TB appears to be on the rise in Africa. A recent study in 
Kwazulu-Natal, South Africa, where a high proportion 
of people infected with TB are HIV-positive, showed 
that 4% of 44 TB patients had multi-drug resistant 
TB. Of these, 4% had XDR, a form of TB resistant to 
not only first-line but also most second-line drugs. All 
except one of these XDR patients died. Major efforts 
must be made now to address the growing threat of 
drug-resistant TB, to ensure diagnosis and treatment 
is available for these patients, to manage care for 
people co-infected with TB and HIV better to prevent 
resistance, and to research better drugs for first-line 
and second-line treatment.  
TB programmes familiar with DOTS have been slow 
to adopt new approaches, and staff are not receiving 
appropriate training. This means that it is still often 
very difficult to get agreement on treatment for smear-
negative or extra-pulmonary TB patients, and where 
treatment is possible there are long delays. These delays 
can mean the difference between life and death for 
many co-infected patients.
“The problem starts with the inpatients who sometimes 
can’t give a sputum sample. You really have to go over 
and beg for treatment. It’s difficult, particularly at the 
weekend. The TB clinic shuts at 3 pm and at the weekend 
so if anyone comes in after that then it is difficult to get 
drugs.” 
	 —	Dr	Helen	Bygrave,	MSF	doctor,	Nigeria.
Unfortunately, a rigid DOTS approach with the 
emphasis on treating smear-positive patients can 
actively discourage programmes from treating HIV 
patients. The effect of DOTS has been that programmes 
have neglected smear-negative and extra-pulmonary 
patients. Encouragingly, the more recent ‘Expanded 
Framework for DOTS’ addresses some of the failings of 
the traditional DOTS approach. However, the reality is 
that things are changing far too slowly.
The slow implementation of new approaches is costing 
lives. DOTS was not designed  to cope with the current 
situation in countries with high HIV rates. It serves 
co-infected patients very poorly. A  study of South 
African gold miners showed that TB rates among 
miners rose four-fold over a -year period despite a 
good DOTS programme being in place since 0. The 
system of direct observation of treatment is a heavy 
burden on staff and patients and is not evidence-based.
“Because of the protocol, smear-negative patients are not 
followed up, meaning that many TB patients go without 
treatment. Many of these patients are not only TB patients, 
but also HIV patients and therefore they die of a treatable 
disease. But the protocol in Zambia makes it very hard for 
me to treat these patients for TB, because I need to have a 
test proving that they have TB. That is a problem because 
HIV patients often produce a negative TB test, even if they 
do have it. It is stupid that protocols are so strict that it 
stops me treating people for TB and preventing them from 
dying. We can save HIV patients from dying if we treat 
them for TB.” 
	 —	Dr	Charles	Ssonko,	Medical	Team	Leader	for	
MSF,	Zambia.
what iS dotS? 
DOTS stands for ‘Directly Observed 
Treatment, Short Course’. Since 1993, this has 
been the standard of care for TB promoted by 
the World Health Organisation. Key elements 
of the DOTS approach include a focus on 
diagnosing and treating ‘sputum-’ or 
‘smear-positive’ patients who are a risk since 
they can spread the disease easily. Treatment 
is ‘short’ using a combination of pills for 6 or 
8 months. Pill-taking is directly observed by 
a health worker to ensure that patients take 
all drugs. This should both ensure cure and 
reduce the risk of resistance developing. 
4
the eStabliShed tb treatMent 
SYSteM failS hiv patientS
The traditional approach to TB treatment is called ‘DOTS’. DOTS mainly focuses on treating people 
seen as a risk to public health – those who cough up large numbers of tuberculosis bacteria. 
Most people infected with HIV and TB do not do this, and so have not been seen as a priority for 
treatment.   
eXpanded fraMeworK for dotS
The World Health Organisation has recognised the inadequacy of DOTS in responding to TB/HIV 
co-infected people and has identified new approaches to ensure they are not neglected. These 
include aiming to use only 6-month treatment courses, reducing the insistence on having high 
proportions of smear-positive patients in high HIV prevalence settings, and ensuring that all 
non-smear-positive patients still get the best treatment. They also include linking TB treatment to 
HIV testing, cotrimoxazole provision, and AIDS care including ARVs.
However, in many settings, almost nothing is happening on the ground. For several years it has 
been clear that the 6-month treatment course is an improvement over the 8-month course, especially 
for co-infected cases. Yet many countries where MSF works, such as Angola, Republic of Congo, 
Liberia, Nigeria, Uganda, and Zambia, still use the 8-month regimen.
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tb and hiv prograMMeS continue 
to worK in iSolation
The separate worlds of TB and HIV are a huge 
barrier in tackling these diseases. Most countries 
have programmes designed specifically to 
manage TB, focusing on the public health risk of 
spread of the disease and prevention of resistance 
to the drugs used. These so-called ‘vertical’ 
programmes usually operate quite separately 
from the rest of the health system. 
HIV care, though it has developed much more recently, 
also developed in a vertical fashion. Unfortunately 
there has been little cooperation between TB and HIV 
programmes. Despite clear statements from the World 
Health Organisation and others on the importance 
of integration and cooperation very little is changing 
on the ground. The vast majority of co-infected 
patients are still failing to access care and TB and HIV 
programmes continue to work in isolation from each 
other.
This means that in many programmes where MSF has 
developed a focus on HIV care there has been a struggle 
to ensure that patients receive good quality TB care. 
Lack of funding and focus on TB have left co-infected 
patients facing a two-tier service: high quality care for 
HIV providing they can attend the centralised health 
clinic, and low quality care for TB often available 
closer to their homes. Those patients with HIV who 
live far from the nearest hospital will not be able to get 
care, and TB patients with forms of TB that cannot be 
diagnosed or treated in the local clinic will also suffer. 
Increasingly it is clear that the best way to ensure good 
care for co-infected patients is to provide care for both 
TB and HIV at the same site – an integrated service. 

Estimated HIV prevalence in new adult TB cases
eStiMated hiv prevalence in new adult tb caSeS 
(Figure reproduced from WHO report Global tuberculosis control: Surveillance, planning, financing)
Countries where MSF provides 
antiretroviral treatments as 
well as treatment or support 
for TB patients.
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0% or more
No estimate
Countries where MSF provides antiretroviral 
treatment as well as ensuring treatment for TB 
patients.0
MYanMar
MSF is the largest provider of HIV/AIDS care 
in Myanmar. In the city of Yangon, MSF staff 
have started 2,500 HIV-positive patients on 
antiretroviral treatment.  The Myanmar project 
has also provided medical care to more than 
6,000 people with TB.

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learning froM eXperience
Treatment of TB or HIV/AIDS is usually organised in vertical systems. Integration of HIV and TB 
treatment must be a priority. MSF has begun to offer routine HIV testing and counselling for all TB 
patients and HIV patients are regularly monitored for signs of TB.
6.1 tb and hiv MuSt be tacKled 
together
Integration of TB and HIV services must be a priority. 
There is overlap in terms of who is affected and the 
approach to diagnosis and treatment, and in terms of 
the similar needs for monitoring, funding, staffing, 
community support, nutritional support, drug supply, 
and training. 
“TB systems are usually vertical organized systems. In 
every town or district you will have a TB system. Next 
to it there might be another vertical organized system for 
AIDS. You go for your AIDS infection to the AIDS doctor 
and for your TB to the TB doctor. This is of course an extra 
burden for the patient and poor medical practice. In MSF’s 
Myanmar programme we don’t have that problem because 
in our clinic we treat both. There is not an AIDS doctor 
and a TB doctor. We have a doctor who treats patients 
whatever you have.
	 —	Dr	Frank	Smithuis,	Head	of	Mission	and	
Medical	Coordinator,	Myanmar.
MSF staff involved in the care of HIV patients 
are trained to look regularly for signs of TB, and 
programmes have recently begun to offer routine HIV 
counselling and testing for all TB patients. Where the 
uptake is low, we attempt to address the barriers to 
testing. These barriers include:
• Cost (MSF always provides the test free of charge);
• The testing centre being too far away (MSF tries to 
ensure the test is always available in the same place 
that the patient is being treated for TB);
• Lack of patient understanding about the reason to 
take a test (MSF staff take time to explain the benefits 
of testing). 
Wherever testing is offered we try to ensure that full 
care and support, including ARV treatment, is also 
available. 
MSF also acknowledges that nutritional support is an 
essential part of treatment and ensures that all patients 
receive enough to eat along with their supply of drugs. 
HIV patients starting their treatment on ARVs are 
provided with balanced food for an initial period of 
three months. To ensure that patients are using their 
food rations themselves, their families are provided 
with support as well.
reaSonS to 
integrate tb and 
hiv prograMMeS 
•  The two diseases often exist in the same person;
•  They both require the diagnosis and treatment 
of the other to achieve the best results from the 
treatment;
•  They both rely on a good drug supply;
•  Both treatments must be taken carefully by the 
patients for a long time;
•  If the drugs are not taken daily the patient will 
not respond well to treatment;
•  Poor adherence can lead to drug resistance;
•  A huge additional burden is placed on both the 
patient and the health system if such similar 
diseases are treated by different people and at 
different locations
 4 
6.2 iMproving diagnoSiS of tb
Health workers can maximise the chance of making a 
correct and timely diagnosis by ensuring good quality 
sputum collection and microscopy. MSF is focusing 
on improving the routine examination of sputum and 
the use of concentration methods to increase sample 
quality.
“The instructions given to produce sputum influence the 
quality of the sputum and therefore influence the outcome 
of the test. MSF currently runs workshops in the Rural 
Health Centres (rural clinics) explaining to community 
health workers how to collect sputum. I think we should 
continue with these workshops on a regular basis because 
it is very important to get good samples.” 
	 —	Jairo	Mbewe,	Laboratory	Technician	for	MSF,	
Nchelenge,	Zambia.
In Khayelitsha, South Africa, the use of fluorescent 
microscopy to diagnose TB of the lung has increased 
detection rates by 0%. We are also looking at ways 
of simplifying and speeding up culture for TB  for 
diagnosis and for  testing for drug resistance. We 
caSe StudieS: 
integration 
MaKeS a real 
difference
South africa
In the MSF project in Lusikisiki, South Africa, 
where around 66% of TB patients are HIV-
positive, integration has made a real difference. 
In July 2006, after an integrated training, nurse 
and community carers in eight out of nine 
primary clinics started to routinely offer HIV 
testing to TB patients. The proportion of TB 
patients aware of their HIV status increased 
from 45% in July 2006 to 75% in September. By 
contrast, in the one clinic that did not integrate 
care and where PITC (Provider Initiated 
Counselling and Testing) was not routine, only 
29% of people took an HIV test. 
Malawi
MSF has also tried to decentralise and 
integrate treatment and follow-up care to 
increase its acceptance and accessibility. For 
example, in Malawi, initially only 44 (13%) of 
352 TB patients who needed ARVs attended 
for follow-up and actually received their 
treatment. This was found to be due to the 
distance they would have to travel to get ARV 
treatment. They managed TB treatment 
because it was delivered from their local 
clinic, but they could not afford to travel in to 
town for HIV care. The only way to solve this 
problem was to provide the HIV care at the 
local clinic, alongside the TB care. 
are assessing clinical algorithms to diagnose TB in 
HIV-positive children, which is one of the greatest 
challenges in providing treatment.
Ultimately, however much the tools are improved, 
HIV-positive patients will often have TB that cannot be 
definitively diagnosed. To ensure that these people do 
not fall through the net, solid clinical skills training is 
required.  
6.3 coMMunitY involveMent
The lack of trained staff presents a huge barrier to 
ensuring appropriate services for people with TB and 
HIV. The problem is especially severe in rural areas 
and in conflict-affected settings. MSF programmes 
are seeking to mitigate this problem by shifting tasks 
to less highly trained health staff and to communities 
and people living with HIV/AIDS themselves; by 
providing more training for doctors and nurses; and by 
ensuring that services are integrated wherever possible 
to use available staff more efficiently. However, these 
approaches need to be expanded. 
In MSF programmes, people living with HIV are often 
recruited or volunteer to help educate and care for 
others with the disease. Those involved with TB or HIV 
in the community are being trained in the care and 
support of those with both diseases. They are trained 
to recognise the signs of both diseases to ensure people 
come for diagnosis and treatment before it is too late. 
They help patients adhere to their drug regimen; 
recognise patients’ problems and encourage them to 
seek health care early; and even provide treatment and 
care themselves. They have proved invaluable in: 
• addressing stigma and increasing awareness to 
encourage people to test or seek treatment if sick;
• providing friendship, support, and health care to 
people with HIV/AIDS;
• ensuring that this support is accessible without the 
need to travel far;
• helping those on treatment to keep taking it properly;
• tracing those who have dropped out of treatment and 
helping them return to care;
• reducing the burden placed on doctors and nurses in 
clinics.
“If I see someone sick in my community with symptoms 
of TB, I tell them to get tested. I never forget to mention 
that they should get tested for HIV as well. I know how to 
recognize TB. As a Voluntary Community Worker, I also 
visit sick patients that have already been tested, just to 
support them.” 
	 —	Mwansa,	40	years	old,	Zambia.	He	had	been	co-
infected	with	TB	and	HIV.
MSf reSearch
MSF is conducting operational research to try 
to ensure that people in need receive treatment. 
Old approaches are being assessed and 
adapted, and new tests and drugs are being 
applied. We are also pushing for greater 
international support for research and 
development of new diagnostic tools and 
treatments. A few examples of the research 
being carried out by MSF include:
•  Documenting the feasibility and impact of  
routine TB screening in HIV clinics;
•  Rapid field appropriate techniques for TB 
culture, including techniques such as MGIT 
(Mycobacteria Growth Indicator Tube);
•  Optimising use of old diagnostic techniques 
(smear, cytology, concentration);
•  Monitoring the impact of charging fees on  
patients’ access to and standard of care;
•  Implementing and monitoring the impact  
of integrated approaches to care;
•  Evaluating TB and TB/HIV diagnostic  
algorithms.
volunteer 
coMMunitY worKer 
—   Masautso, 37 years old, is a Voluntary Community 
Worker, who helps detect and take care of TB and 
HIV patients. He had been co-infected with TB 
and HIV .
“I am fine now. I have had some tough times, but I survived. 
When I meet other patients that are reluctant to take a TB or 
HIV test, I always try to convince them. I give myself as an 
example. I was once also very sick, but now I am as strong 
as a horse. I would like to say to other co-infected patients 
that life is worth living, you should get treatment. You only 
have one life, you should take this opportunity and get some 
treatment. Without it they will die. And that is completely 
unnecessary.
Since 2004, every Monday and Friday morning I work as a 
psycho-social counsellor for HIV patients. I speak to 
patients who are about to get an HIV test and explain to 
them what the disease is and that they shouldn’t be afraid. 
After they are tested, and if they are positive, I explain to 
them what treatments there are. 
Since 2005, I have been working as a TB counsellor as well. 
That means I go into the villages to find sick patients that 
might be infected with TB. I tell them they should get 
tested. I send them to the clinic and I take a sputum sample 
from them to get tested. 
As a community worker I also visit the sick that are in bed. 
And I follow up patients that are taking HIV or TB treatment. 
All this I do voluntarily. On Tuesday, Wednesday, and Thurs-
day I work as a farmer and try to earn my living with that.” 
action now to prevent
More needleSS deathS
There is a stark contrast between the rhetoric and promises surrounding 
HIV and TB internationally, and the experiences of our patients and those 
who care for them. Greater urgency is needed in implementing accessible 
services for people confronted with this double disease burden. 
To combat TB and HIV and stop the rising tide of needless deaths, action 
in several areas is needed now:
• Routine HIV testing and care must be made available and accessible for 
all TB patients and vice-versa;
• Shorter (- rather than -month) TB treatment regimens must be used;
• The DOTS policy has been revised, but adapted strategies to cope with 
the effects of the HIV epidemic need to be implemented on the ground. 
HIV patients with smear-negative or extra-pulmonary TB must not miss 
out on treatment;
• Better tools for diagnosing TB are desperately needed, along with drugs 
that can reduce the length of treatment and pill burden. Increased 
support for research and development must be made available to meet 
these goals and ensure that the tools developed are affordable;
• Long-term goals of effective TB and HIV vaccines must be addressed 
– but should not distract from the immediate and more achievable steps 
that must be taken now.
Without immediate action, these epidemics will continue to 
claim the lives of millions of people every year.40
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